00

Hualan Biological Engineering IncSHE 002007 Stock Report

Last reporting period 30 Jun, 2024

Updated 18 Sep, 2024

Last price

Market cap $B

3.576

Middle

Exchange

XSHE - Shenzhen Stock Exchange

002007.SZ Stock Analysis

00

Uncovered

Hualan Biological Engineering Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

80/100

Moderate score

Market cap $B

3.576

Dividend yield

1.73 %

Shares outstanding

1 826.65 B

Hualan Biological Engineering, Inc. engages in the research, development, production, and sale of blood products, vaccines, and genetically engineered products. The company is headquartered in Xinxiang, Henan and currently employs 2,927 full-time employees. The company went IPO on 2004-06-25. The company also produces vaccine products and biological engineering products. The firm's main products include human albumins, human immunoglobulin for intravenous injection, human immunoglobulin, human coagulation factors, human rabies immunoglobulin, human tetanus immunoglobulin and influenza vaccines, among others. The firm mainly operates its businesses in domestic markets.

View Section: Eyestock Rating